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Summary
 
Idiopathic pulmonary alveolar proteinosis (I-PAP) is a rare disease of unknown etiology in
which the alveoli fill with lipoproteinaceous material. We report here that I-PAP is an autoim-
mune disease with neutralizing antibody of immunoglobulin G isotype against granulocyte/
macrophage colony-stimulating factor (GM-CSF). The antibody was found to be present in all
specimens of bronchoalveolar lavage fluid obtained from 11 I-PAP patients but not in samples
from 2 secondary PAP patients, 53 normal subjects, and 14 patients with other lung diseases. It
specifically bound GM-CSF and neutralized bioactivity of the cytokine in vitro. The antibody
was also found in sera from all I-PAP patients examined but not in sera from a secondary PAP
patient or normal subjects, indicating that it exists systemically in I-PAP patients. As lack of
GM-CSF signaling causes PAP in congenital cases and PAP-like disease in murine models, our
findings strongly suggest that neutralization of GM-CSF bioactivity by the antibody causes dys-
function of alveolar macrophages, which results in reduced surfactant clearance.
Key words: autoantibody • granulocyte/macrophage colony-stimulating factor • 
pulmonary alveolar proteinosis • alveolar macrophage • surfactant protein
 
P
 
ulmonary alveolar proteinosis (PAP) is a heterogeneous
group of congenital and acquired diseases characterized
by accumulation of excessive surfactant composed of phos-
pholipids and surfactant proteins designated as surfactant
protein (SP)-A, -B, -C, and -D in the alveoli and terminal
bronchioli (1, 2).
Most PAPs are acquired cases that predominantly affect
adults, including idiopathic (I)-PAP and secondary (S)-PAP
cases. S-PAP was reported in several clinical settings, such
as pulmonary infection, hematologic malignancies, and in-
halation of chemicals and minerals (3). The most common
form is I-PAP, but its etiology is still not known. Standard
therapy of the disease is whole lung lavage, which usually
provides temporal symptomatic relief (4). The accumula-
tion of surfactant protein is due to reduced surfactant clear-
ance rather than excessive secretion, and SP-A specifically
increases in the lungs of PAP patients as compared with
other surfactant proteins (5, 6). Because alveolar macro-
phages (AMs) catabolize SP-A (7), it was suggested that de-
fective SP-A clearance in AMs caused PAP.
One kind of congenital form is associated with defective
expression of the 
 
b
 
 chain of the GM-CSF receptor in he-
matopoietic cells (8). In mice, a defect in the gene for GM-
CSF or the 
 
b 
 
chain of the GM-CSF receptor results in
PAP-like disease with alveolar accumulation of surfactant
(9, 10). Thus, lack of GM-CSF signaling seems to cause
AM dysfunction that leads to PAP.
Recently, we found a factor in the bronchoalveolar la-
vage fluid (BALF) from I-PAP patients that neutralized the
bioactivity of GM-CSF (11). The factor directly bound
GM-CSF and blocked its binding to GM-CSF receptors
on the cells. Here we show that the factor is a neutralizing
autoantibody directed against GM-CSF and present in the
BALF and sera of patients with I-PAP. We propose that
the autoantibody against GM-CSF is a causative agent for
I-PAP.
 
Materials and Methods
 
Subjects.
 
We obtained BALF from 11 patients with I-PAP, 2
patients with S-PAP, 14 patients with other lung diseases (3 cases
each of sarcoidosis and collagen vascular lung disease; 2 cases each
of interstitial pneumonitis, hypersensitive pneumonitis, and eo-
sinophilic pneumonia; and 1 case each of bronchiolitis obliterans
organizing pneumonia and lung cancer), and 53 normal subjects.
Diagnosis of PAP was based on biochemical analysis of BALF
and histopathological findings of lung biopsy. The I-PAP patients
had no history of hematological disorders, infectious diseases, or 
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toxic inhalation. Two S-PAP patients were in the blast phase of
chronic myelogenous leukemia. 5 of 11 I-PAP patients, 1 of 2
S-PAP patients, and 30 normal subjects underwent venipuncture
to obtain sera at various periods after bronchoalveolar lavage.
Written informed consent to participate in this study was ob-
tained from all subjects.
 
Cytokines, Antibodies, and a Cell Line.
 
Recombinant human
(rh)GM-CSF was provided by Kirin Brewery Co., Ltd. (Taka-
saki, Japan), and 
 
125
 
I–Bolton Hunter–labeled rhGM-CSF was
purchased from NEN Life Science Products. rhIL-3 was pur-
chased from R & D Systems, Inc. Biotinylated or nonlabeled rat
anti–human GM-CSF mAb (BVD2-21C11 and BVD2-23B6,
respectively) was purchased from PharMingen. Peroxidase-
labeled rabbit anti–human IgA, -D, -E, -G, and -M polyclonal
antibodies were purchased from DAKO Corp. A GM-CSF– or
IL-3–dependent cell line, TF-1 (12), was provided by Dr. Kita-
mura (The Institute of Medical Science, The University of
Tokyo, Tokyo, Japan).
 
Blot Assay with 
 
125
 
I–GM-CSF.
 
Proteins in BALF or sera
were subjected to SDS-PAGE using gradient gel (2–15%) under
nonreducing conditions at 30 mA constant current for 150 min.
Separated proteins were transferred electrophoretically to a poly-
vinylidene fluoride (PVDF) membrane at 12 V constant voltage
for 75 min. The membrane was fixed with 10% (vol/vol) acetic
acid and 50% (vol/vol) methanol, stained with Coomassie bril-
liant blue solution, washed with methanol, and treated with a
blocking reagent (PBS supplemented with 1% [wt/vol] BSA and
0.1% [vol/vol] Tween 20) overnight at 4
 
8
 
C. The membrane was
then incubated with 0.16 nM 
 
125
 
I–GM-CSF for 1 h at room
temperature. After washing, the membrane was exposed to x-ray
film for 4 d.
 
Competition Assay of GM-CSF Binding to the mAb in ELISA.
 
The method of this assay was described previously (11). In brief,
after coating a micro-ELISA plate with anti–human GM-CSF
mAb (BVD2-23B6), rhGM-CSF and BALF were incubated in
the wells. rhGM-CSF bound to BVD2-23B6 antibody was de-
tected using biotinylated anti–human GM-CSF mAb (BVD2-
21C11) and streptavidin conjugated to horseradish peroxidase.
Color was developed using tetramethylbenzidine, and the absor-
bance was measured at 450 nm using a microplate spectrometer
(model 3550; Bio-Rad Labs.). Binding activity was calculated
with the following equation: binding activity 
 
5
 
 1 
 
2
 
 detected
GM-CSF (ng/ml)/applied GM-CSF (ng/ml).
 
Purification of the GM-CSF Binding Protein.
 
BALF was centri-
fuged at 1,000 
 
g
 
 for 5 min. To remove lipoid materials, the super-
natant was mixed vigorously with an equal volume of 1-butanol,
and the mixture was centrifuged at 1,000 
 
g 
 
for 5 min. After re-
moving the butanol layer, the procedure was repeated. The aque-
ous layer was dialyzed against 10 mM ammonium acetate, pH
7.0, and lyophilized. Delipidated BALF was purified by using Hi-
Trap SP column, a cation exchange column (equilibrated with
20 mM ammonium acetate, pH 6.0, and eluted with a linear so-
dium chloride gradient); HiTrap Q column, an anion exchange
column (equilibrated with 20 mM Tris-HCl, pH 9.0, and eluted
with a linear sodium chloride gradient); Superose 12 column, a
gel filtration column (equilibrated with PBS containing 0.1%
[vol/vol] NP-40 and eluted with the same buffer); RESOURCE
Q column, an anion exchange column (equilibrated with 20 mM
Tris-HCl, pH 9.0, and eluted with a linear sodium chloride gra-
dient); and RESOURCE S column, a cation exchange column
(equilibrated with 20 mM ammonium acetate, pH 6.0, and
eluted with a linear sodium chloride gradient). All of these col-
umns were from Pharmacia Biotech.
 
Purification of Igs.
 
Delipidated BALF was applied on recombi-
nant protein A affinity column (Pharmacia Biotech) equilibrated
with 20 mM sodium phosphate, pH 7.0. Ig bound to the column
was eluted by pH gradient (pH 3.0–7.0).
 
NH
 
2
 
-terminal Sequencing of Protein.
 
NH
 
2
 
-terminal sequenc-
ing of protein was performed by the phenyl isothiocyanate
method using the HP G1005A NH
 
2
 
-terminal protein sequencing
system (Hewlett-Packard Bioscience Products).
 
Antigen Capture Assay to Determine the Isotype of the Antibody.
 
Various concentrations of Ig purified from BALF of an I-PAP pa-
tient (39–5,000 ng/ml) were transferred to micro-ELISA plates
coated with 1 
 
m
 
g/ml rhGM-CSF, and the plate was kept at room
temperature for 1 h. After washing, 0.3 
 
m
 
g/ml of peroxidase-
labeled anti–human IgA, -D, -E, -G, or -M polyclonal antibody
was added to each well and incubated at room temperature for 1 h.
Color was developed using tetramethylbenzidine, and the absor-
bance was measured at 450 nm.
 
3-[4,5-Dimethylthiazol-2yl]-2,5-Diphenyltetrazolium Bromide As-
say.
 
The method of this assay was described previously (13). In
brief, TF-1 cells (2 
 
3
 
 10
 
4
 
 cells/well) were incubated for 3 d with
1 ng/ml of rhGM-CSF or rhIL-3 and 1 
 
m
 
g/ml of Igs purified
from BALF of an I-PAP patient. To the culture, 5 
 
m
 
g/ml
of 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium  bromide
(MTT; Sigma Chemical Co.) was added and incubated. After
formation of formazan crystals, isopropanol/HCl was added to
dissolve the crystal, and the absorbance was measured at 595 nm.
Figure 1. Occurrence of GM-CSF binding factor in BALF from
I-PAP patients. Proteins in BALF from I-PAP patients (lanes 1–11),
S-PAP patients (lanes 12–13), normal subjects (lanes 14–18), and patients
with other lung diseases (namely sarcoidosis, lane 19; collagen vascular
lung disease, lane 20; interstitial pneumonitis, lane 21; hypersensitive
pneumonitis, lane 22; and eosinophilic pneumonia, lane 23) were sub-
jected to SDS-PAGE under nonreducing conditions, stained with Coo-
massie blue (top panel), and assayed with 125I–GM-CSF (bottom panel).
Molecular mass markers are shown at left (kD). Radioactive 180-kD
bands are seen in all I-PAP samples but not in samples from S-PAP pa-
tients, normal subjects, or patients with other lung diseases. No such band
was detected in BALF from an additional 48 normal subjects or 9 patients
with other lung diseases. 
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Results
 
Occurrence of GM-CSF Binding Factor in BALF.
 
Occur-
rence of the GM-CSF binding factor in BALF supernatant
was studied from 80 donors, including 11 I-PAP patients.
As shown in Fig. 1, blot assay with 
 
125
 
I–GM-CSF gave a
single band with a molecular mass of 180 kD in all I-PAP
cases examined. In contrast, no band was detected in S-PAP
patients, normal subjects, or patients with other lung
diseases such as sarcoidosis, collagen vascular lung disease,
interstitial pneumonitis, hypersensitive pneumonitis, and
eosinophilic pneumonia.
 
Purification and Characterization of the GM-CSF Binding
Factor.
 
The binding factor in BALF was purified by cat-
ion- and anion-exchange chromatography and gel filtration
chromatography (Fig. 2 A). For evaluation of binding ac-
tivity, a competition assay of GM-CSF binding to the mAb
(BVD2-23B6) in ELISA was used. The purified protein
showed a single band of 180 kD on SDS-PAGE under
nonreducing conditions and two bands of 28 and 57 kD
under reducing conditions (Fig. 2 B). 
 
125
 
I–GM-CSF bind-
ing to the purified 180-kD protein was confirmed by blot
assay (Fig. 2 C), and bound 
 
125
 
I–GM-CSF was released
when treated with citrate buffer, pH 2.0 (data not shown).
 
The GM-CSF Binding Factor Is an Antibody against the Cy-
tokine.
 
The 57-kD band was electroblotted onto a PVDF
membrane and sequenced directly. The NH
 
2
 
-terminal se-
quence of the 57-kD protein was EVQLVESGGG-
LVQPGGSLRL, identical to the NH
 
2
 
-terminal sequence
of human Ig H chain. The data suggest that the GM-CSF
binding protein in the BALF is an antibody. To show that
the binding factor is actually an antibody, Ig in BALF from
 
an I-PAP patient was isolated using a recombinant protein
A column. Ig eluted from the column by changing pH gra-
dient showed 
 
125
 
I–GM-CSF binding activity (Fig. 2 D).
Specificity of binding to GM-CSF was demonstrated by ef-
fective competition of 
 
125
 
I–GM-CSF binding with nonra-
dioactive GM-CSF (Fig. 2 E). 
 
125
 
I–GM-CSF binding ac-
tivity was not affected by the presence of nonspecific
human Ig (data not shown).
 
Bioactivity of the Isolated Ig.
 
To confirm the bioactivity
of isolated Ig, its inhibitory effect on growth of the TF-1
cell line was examined using the MTT assay. Growth of
TF-1 cells is dependent on either GM-CSF or IL-3. The Ig
purified from BALF inhibited GM-CSF–dependent
growth of TF-1 cells but not IL-3–dependent growth (Fig.
3). The results indicate that the antibody inhibits growth of
this cell line by neutralizing the bioactivity of GM-CSF.
 
The Isotype of the Autoantibody.
 
The isotype of the anti-
body was determined by antigen capture assay. The Ig cap-
tured by GM-CSF reacted with only anti–human IgG,
whereas no other antiisotype antibody reacted, indicating
that the isotype of the antibody is IgG (data not shown).
 
Presence of the Autoantibody in the Serum.
 
To know whether
the I-PAP patients have circulating antibody against GM-
CSF, we performed a blot assay with 
 
125
 
I–GM-CSF of sera
from 36 donors, including 5 I-PAP patients, 1 S-PAP patient,
and 30 normal subjects who underwent bronchoalveolar la-
vage during this study. Serum samples from all I-PAP pa-
tients showed a single 180-kD band, whereas no such band
was detected in samples from the S-PAP patient and nor-
mal subjects (Fig. 4). Interestingly, the band was observed
Figure 2. Characterization of GM-CSF binding factor in BALF from I-PAP patients. Molecular mass markers are shown at left in A–E (kD). (A) Pro-
tein profiles of SDS-PAGE at each purification step (stained by silver stain). Delipidated BALF (lane 1) was purified using HiTrap SP (lane 2), HiTrap Q
(lane 3), Superose 12 (lane 4), RESOURCE Q (lane 5), and RESOURCE S columns (lane 6). (B) SDS-PAGE of the purified protein under nonreduc-
ing (lane 1) and reducing conditions (lane 2). Stained by silver stain. (C) Coomassie blue staining (lanes 1 and 2) and GM-CSF binding activity (lanes 3
and 4) of crude (lanes 1 and 3) and purified factor (lanes 2 and 4). (D) GM-CSF binding activity of Ig isolated using recombinant protein A column. Pro-
tein profile stained with Coomassie blue (top panel) and results of 125I–GM-CSF binding (bottom panel) are shown. Lane 0, delipidated BALF; lanes
1–9, pass-through fractions; lanes 10–14, proteins eluted from column by changing pH gradient. (E) Competition of 125I–GM-CSF binding with nonra-
dioactive GM-CSF. Lane 1, without nonradioactive GM-CSF; lanes 2 and 3, with 50- and 500-fold concentrations of nonradioactive GM-CSF, respec-
tively.  
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even in those from three patients who had entered remis-
sion and whose chest x-rays showed no opacity at the time
of study. The isotype of the antibody in sera was also IgG
(data not shown). These results indicate that the antibody is
not limited to the lung but exists systemically in I-PAP pa-
tients.
 
Discussion
 
We have shown in this paper that autoantibody against
GM-CSF is present in the lungs and sera of I-PAP patients
but not in those of S-PAP patients, normal subjects, or pa-
tients with other lung diseases. Because GM-CSF is a key
factor for maintaining the differentiation and proliferation
of macrophages, dysfunction of AMs due to the neutraliza-
tion of GM-CSF bioactivity by an autoantibody is a plausi-
ble explanation for the pathogenesis of human I-PAP. In
fact, AMs from patients with active acquired PAP are
known to be functionally impaired (14, 15). Furthermore,
one type of congenital PAP was known to be associated
with a defect of the GM-CSF receptor, and in murine
models, knockout of the gene for GM-CSF or its receptor
induced PAP-like disease. The disease in these murine
models was corrected by transgenic expression of GM-CSF
in the pulmonary epithelia or bone marrow transplantation
from wild-type mice (16, 17).
It is increasingly understood that sera in some healthy
and diseased individuals contain autoantibodies against cy-
tokines. Natural antibodies have been reported against rh
IL-1
 
b
 
, IL-2, IL-8, and TNF-
 
a
 
 (18–21). Most of these au-
toantibodies were neutralizing antibodies and interfered
with the binding of cytokines to receptors by simple com-
petition (19–21). Recently, it was reported that anti–GM-
CSF autoantibody was frequently detected in pharmaceuti-
cally prepared human IgG (22) and that 0.3–2% of sera had
a low titer of anti–GM-CSF antibody (22, 23). However, it
was not reported that autoantibody against GM-CSF is as-
sociated with any disease or symptoms. Our results strongly
suggest that I-PAP is an autoimmune disease with neutral-
izing autoantibody against the cytokine. As mentioned
above, previous work in the patient case report and in mice
has established that impaired production or action of GM-
CSF can cause PAP. It is, therefore, reasonable to ascribe
causality to the presence of autoantibody in the cases pre-
sented here, frequently and solely in the patients with I-PAP.
This is, therefore, the first disease for which it can be ar-
gued that the cause is an autoantibody to a cytokine.
It is not clear at the time of this writing why autoanti-
body is generated in I-PAP patients. One possibility is that
the autoantibody was provoked by a cross-reactive antigen,
possibly from infectious pathogen(s). Alternatively, the au-
toantibody was generated to endogenously regulate GM-
CSF bioactivity.
Although the functional consequences are predomi-
nantly manifest within the lung, our data suggest that the
pathophysiologic disorder of I-PAP may originate from the
systemic generation of autoantibody against GM-CSF. In
this regard, recent clinical trials of GM-CSF administration
to acquired PAP are intriguing (24). The hematopoietic
response to GM-CSF in the patients was attenuated. The
impaired response was not due to altered expression of
GM-CSF receptor on PBMCs. It is possible that the ad-
ministrated GM-CSF was neutralized by anti–GM-CSF
antibody before it reached the target organs.
Finally, our observations have therapeutic implications.
Whole lung lavage provides temporary remission in most
cases, but additional lavage is required in more than 50% of
patients (25). Measurement of the autoantibody in the lung
after whole lung lavage may identify patients who require
further therapy or who have risk for recurrence.
Figure 3. Inhibition of TF-1
cell growth by isolated Ig. Con-
centrations used: 1 ng/ml GM-
CSF, 100 mg/ml delipidated
BALF, 1 mg/ml isolated Ig, and
1 ng/ml IL-3.
Figure 4. Occurrence of anti-
body against GM-CSF in sera
from I-PAP patients. Proteins in
sera from I-PAP patients (lanes
1–5), an S-PAP patient (lane 6),
and normal subjects (lanes 7–11)
were subjected to SDS-PAGE
under nonreducing conditions,
stained with Coomassie blue (top
panel), and assayed for 125I–GM-
CSF binding (bottom panel). Mo-
lecular mass markers are shown at
left (kD). Radioactive 180-kD
bands are seen in all I-PAP sam-
ples but not in samples from the
S-PAP patient and normal sub-
jects. No such band was detected
in sera from 25 additional normal
subjects. 
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